摘要
目的 探讨加贝酯、奥曲肽和奥美拉唑联合应用在预防内镜下逆行胰胆管造影术(ERCP)术后胰腺炎(PEP)中的作用.方法 将235例ERCP术后患者随机分为治疗组(125例)和对照组(110例).治疗组ERCP术后应用加贝酯1 mg/(kg·h)持续静脉滴注12 h;奥曲肽0.1 mg皮下注射,每12小时1次,12 h内应用;奥美拉唑40 mg静脉滴注,每12小时1次,24 h内应用.对照组ERCP术后静脉滴注生理盐水500 ml.ERCP术前、术后3、12、24 h检测血清淀粉酶并观察PEP的发生率.结果 治疗组和对照组ERCP术后PEP的发生率分别3.20%和11.82%(P<0.01),高淀粉酶血症的发生率分别为18.40%和39.09%(P<0.05).结论 加贝酯、奥曲肽和奥美拉唑联合应用可减少PEP和高淀粉酶血症的发生率.
Objective To investigate the prophylactic effect of gabexate mesilate, octreotide and omeprazole on post - ERCP pancreatitis. Methods Two hundred and thirty - five post ERCP patients were randomized into therapeutic group (125 cases) and control group (110 cases). After the operation of ERCP, patients in the therdpeutic group were treated with gabexate mesilate 1 mg/(kg·h) by contin-ous intravenous infusion for 12 hours, Octreotide 0. 1 mg by subcutaneous injection per 12 hours for 12 hours, Omeprazole 40 mg by intravenous infusion per 12 hours for 24 hours. The patients in the control group were applied with intravenous infusion of nermal saline 500 ml. The levels of serum amylase were detected and the incidence of PEP were observed at pre - ERCP and 5 h, 12 h ,24 h post - ERCP, respectively. Results The incidences of post - ERCP pancreatitis in the therapeatic group and control group were 3. 2% and 11. 82% , respectively ( P < 0. 01 ) , and the percentages of hyperamylasemia were 18.4% and 39.09% Respectively ( P <0. 05). Conclusions The combined use of gabexate, meilate, octreotide and omeprazole can reduce the incidences of PEP and hyperamylasemia.
出处
《中国实用医刊》
2010年第5期28-29,共3页
Chinese Journal of Practical Medicine
